» Articles » PMID: 15627768

Diagnostic Criteria for Irritable Bowel Syndrome: Utility and Applicability in Clinical Practice

Overview
Journal Digestion
Specialty Gastroenterology
Date 2005 Jan 4
PMID 15627768
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aims: Symptom-based criteria have been introduced to aid the diagnosis of irritable bowel syndrome (IBS). Although they have been widely adopted and have proved useful for research purposes by ensuring homogeneity of study populations, there is little information about their utility in routine clinical practice. It was the aim of this study to assess the applicability of the Manning, Rome I and Rome II criteria in the clinical setting and to ascertain how often hospital specialists and general practitioners (GPs) use them.

Methods: Hundred secondary-care IBS patients were assessed for their conformity to these criteria. Forty-eight hospital specialists and 68 GPs were asked about their knowledge and utilization of these criteria.

Results: Seventy-three percent of IBS patients met Rome II diagnostic criteria with 82 and 94% meeting Rome I and Manning, respectively. Approximately 80% of GPs had no knowledge of any of the specific criteria, and only 4% had ever used them. The majority of specialists had knowledge of the criteria, with 70% having used them.

Conclusion: The Rome II criteria are remarkably insensitive and if rigidly applied in the clinical situation would lead to much diagnostic uncertainty. The current lack of interest in them, especially amongst GPs, is unlikely to change unless they can be considerably improved.

Citing Articles

A Cross-Sectional Study about Knowledge, Attitude, and Practices among Primary Health Care Physicians in Jazan Province, Saudi Arabia, Regarding Rome IV Criteria for Diagnosis of Irritable Bowel Syndrome.

Abusageah F, Hakami A, Zogel B, Zaalah S, Alfaifi S, Shubayli S Medicina (Kaunas). 2022; 58(12).

PMID: 36557013 PMC: 9785885. DOI: 10.3390/medicina58121811.


Circulating Anti-cytolethal Distending Toxin B and Anti-vinculin Antibodies as Biomarkers in Community and Healthcare Populations With Functional Dyspepsia and Irritable Bowel Syndrome.

Talley N, Holtmann G, Walker M, Burns G, Potter M, Shah A Clin Transl Gastroenterol. 2019; 10(7):e00064.

PMID: 31356481 PMC: 6708662. DOI: 10.14309/ctg.0000000000000064.


Prevalence and impact of self-reported irritable bowel symptoms in the general population.

Van den Houte K, Carbone F, Pannemans J, Corsetti M, Fischler B, Piessevaux H United European Gastroenterol J. 2019; 7(2):307-315.

PMID: 31080615 PMC: 6498809. DOI: 10.1177/2050640618821804.


Neuromuscular electrical stimulation as an adjunctive therapy to drotaverine hydrochloride for treating patients with diarrhea-predominant irritable bowel syndrome: A retrospective study.

Wang J, Liu J Medicine (Baltimore). 2018; 97(29):e11478.

PMID: 30024524 PMC: 6086520. DOI: 10.1097/MD.0000000000011478.


Pros and Cons While Looking Through an Asian Window on the Rome IV Criteria for Irritable Bowel Syndrome: Pros.

Ghoshal U J Neurogastroenterol Motil. 2017; 23(3):334-340.

PMID: 28672432 PMC: 5503282. DOI: 10.5056/jnm17020.